Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | DNA | IVA |
|---|---|---|
| Price | $11.47 | $3.37 |
| Change today | ▼ 7.57% | ▼ 2.75% |
| Market cap | $772.39M | $794.93M |
| Return, 3 months | +17.9% | -25.7% |
| Return, year to date | +38.0% | -27.6% |
| Return, 1 year | -28.7% | -37.2% |
| P/E (TTM) | -2.3 | -5.6 |
| P/B | 1.8 | 12.0 |
| P/E percentile vs own 5y | 30th | 14th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -48.5% | -12.2% |
| Net profit growth (YoY) | +22.5% | -61.3% |
| Gross margin | 68.0% | – |
| Operating margin | -228.6% | -299,304.1% |
| Net margin | -219.6% | -505,557.1% |
| Return on equity | -56.3% | -989.0% |
| Analyst target vs. price | -39.0% | +360.6% |
| Analyst buy share | 0% | 100% |
| RSI (14) | 57 | 37 |
| 30-day volatility | 125.7% | 63.2% |
| Max drawdown, 1 year | -66.0% | -54.4% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Sell | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
